Mayo Clinic

OPTAC-X and Mayo Clinic Tele-Ems Pilot Proves Resilient During Recent Cellular Service Outages

Retrieved on: 
Friday, March 1, 2024
Hospital, LTE, Emergency medical services, Physician, GEO, First Responder Network Authority, Vital signs, SATCOM, National Guard, Communication, Kymeta, Mayo Clinic, Patient, AT&T, Telecommunications, Immunity, ESA, EMS, LEO, Law enforcement

ORLANDO, Fla., March 1, 2024 /PRNewswire/ -- OPTAC-X's tele-EMS technology with hybrid cellular and SATCOM capabilities that is currently being tested in a Mayo Clinic pilot proved immune to last week's nationwide cellular service outage.

Key Points: 
  • ORLANDO, Fla., March 1, 2024 /PRNewswire/ -- OPTAC-X's tele-EMS technology with hybrid cellular and SATCOM capabilities that is currently being tested in a Mayo Clinic pilot proved immune to last week's nationwide cellular service outage.
  • He reported its network, as activated for the Mayo Clinic pilot, remained fully functional during the entire cellular service outage last week.
  • According to Keith Barr, CTO of OPTAC-X, its immunity to last week's cellular service outage lies in its calculated redundancy.
  • "By combining terrestrial systems like cellular service and a celestial system like SATCOM, OPTAC-X remains resilient despite challenges that often bring other networks down."

HealthTree Foundation Announces Launch of HealthTree Research Hub in Multiple Myeloma

Retrieved on: 
Friday, March 1, 2024
PRO, RWD, EHR, Multiple myeloma, IRB, Emory University, Mayo Clinic, Genetics, Leukemia, Patient, Electronic health record, Lymphoma, Research, Pharmaceutical industry

SALT LAKE CITY, Utah, March 1, 2024 /PRNewswire/ -- HealthTree Foundation, a global non-profit organization using cutting-edge technology that unites patients and researchers to accelerate cures, is excited to announce the release of its highly anticipated HealthTree Research Hub portal.

Key Points: 
  • HealthTree Research Hub is an online research portal that facilitates real-world data (RWD) research.
  • HealthTree Research Hub provides researchers access to over 14,000 myeloma patients who contribute anonymized data to the HealthTree Cure Hub patient portal.
  • HealthTree Research Hub will facilitate over 100 research projects in the next 20 months for myeloma researchers.
  • HealthTree Research Hub will additionally be open for beta research projects in lymphoma, leukemia and MPNs in 2024.

How Cinesteam® Helps Manage Smells From Diabetic Foot

Retrieved on: 
Thursday, February 29, 2024
Diabetes, Smell, Blood, Diabetic foot, Sensation, Pain, Infection, Foot, Diabetic neuropathy, Ulcer, Blister, Mayo Clinic, Peripheral neuropathy, Hypoesthesia, Business, Code, Dentistry

FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Diabetic foot is a common concern for those with diabetes. The condition can lead to chronic wounds that produce highly unpleasant smells. Cinesteam® is a natural-based secondary dressing designed to simply and effectively manage smells like those that come from diabetic foot.

Key Points: 
  • FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Diabetic foot is a common concern for those with diabetes.
  • Cinesteam® is a natural-based secondary dressing designed to simply and effectively manage smells like those that come from diabetic foot.
  • The medical condition comes with many health concerns, one of which is commonly referred to as "diabetic foot."
  • Mayo Clinic reports that as much as 50% of those with diabetes can be affected by diabetic neuropathy, opening the doors for diabetic foot to develop.

Horizon CME Brings Best of ASCO® to San Francisco, Dallas, Phoenix and Los Angeles

Retrieved on: 
Wednesday, February 28, 2024
MD Anderson Cancer Center, Physician, Pharmacist, Annual general meeting, Convention center, Society, University, Mayo Clinic, Clinical professor, USC, CME, Medicine, Pharmaceutical industry

CLACKAMAS, Ore., Feb. 28, 2024 /PRNewswire/ -- Horizon CME will host Best of ASCO® 2024 programs in San Francisco, Dallas, Phoenix and Los Angeles.

Key Points: 
  • CLACKAMAS, Ore., Feb. 28, 2024 /PRNewswire/ -- Horizon CME will host Best of ASCO® 2024 programs in San Francisco, Dallas, Phoenix and Los Angeles.
  • These in-person conferences will bring the most recent oncology scientific findings to physicians, pharmacists and allied health providers in these regions.
  • Best of ASCO® is an officially licensed program of the American Society of Clinical Oncology® (ASCO®), the foremost professional organization representing physicians of all oncology subspecialties.
  • The Best of ASCO® Phoenix will be held July 20 - 21, 2024, at the Westin Kierland Hotel in Scottsdale, Ari.

ISHI Health Secures $4M to Transform Heart Failure Care Across the Disease Risk Spectrum

Retrieved on: 
Thursday, February 22, 2024
SAN, AI, TDV, Ageing, Health, Empowerment, Cardiovascular disease, SMS, Risk, Heart failure, Prevalence, Disability, Mayo Clinic, Death, Patient, Partnership, Pharmaceutical industry

Through a collaboration with Mayo Clinic , ISHI provides precision care to heart failure and cardiometabolic patients.

Key Points: 
  • Through a collaboration with Mayo Clinic , ISHI provides precision care to heart failure and cardiometabolic patients.
  • This allows ISHI to tailor care to each patient's unique heart disease profile, biometric data, and symptoms.
  • ISHI's turnkey, bolt-on model facilitates a complimentary care model, providing swift access to top-tier heart failure specialist care.
  • A dedicated Heart Failure care team promptly intervenes if patient data indicates rising risk, collaborating closely with the primary clinical team.

NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation

Retrieved on: 
Thursday, February 22, 2024
Esophagitis, Tricuspid valve, Denervation, General partnership, Mitral regurgitation, Johnson & Johnson, Mayo Clinic, Clinical professor, Hypertension, Ethicon, Mitral valve, Patient, Disease, Pharmaceutical industry

MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.

Key Points: 
  • MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.
  • The company appointed Todd Berg as Chief Executive Officer to oversee clinical and commercial programs for transeptal and transapical repair of damaged mitral valve chords resulting in regurgitation.
  • Berg has over 30 years of experience successfully developing and commercializing novel medical therapies and holds over 100 U.S. patents.
  • The opportunity to develop a first-line therapy for mitral valve disease, by resolving regurgitation early in the disease state, is incredibly compelling," said Berg.

NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation

Retrieved on: 
Thursday, February 22, 2024
Esophagitis, Tricuspid valve, Denervation, General partnership, Mitral regurgitation, Johnson & Johnson, Mayo Clinic, Clinical professor, Hypertension, Ethicon, Mitral valve, Patient, Disease, Pharmaceutical industry

MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.

Key Points: 
  • MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.
  • The company appointed Todd Berg as Chief Executive Officer to oversee clinical and commercial programs for transeptal and transapical repair of damaged mitral valve chords resulting in regurgitation.
  • Berg has over 30 years of experience successfully developing and commercializing novel medical therapies and holds over 100 U.S. patents.
  • The opportunity to develop a first-line therapy for mitral valve disease, by resolving regurgitation early in the disease state, is incredibly compelling," said Berg.

Zimmer Biomet Receives FDA Clearance for ROSA® Shoulder System - the World's First Robotic Assistant for Shoulder Replacement Surgery

Retrieved on: 
Thursday, February 22, 2024
Robotics, Shoulder, MD, FDA, Food, Zimmer Biomet, Surgeon, MBA, ROSA, Orthopedic surgery, Dynamics, Pterygopalatine fossa, Mayo Clinic, Patient, Anatomy, Dentistry

WARSAW, Ind., Feb. 22, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the ROSA® Shoulder System for robotic-assisted shoulder replacement surgery. ROSA Shoulder is the world's first robotic surgery system for shoulder replacement, and the fourth application for the Company's comprehensive ROSA® Robotics portfolio, which includes the ROSA® Knee System for total knee arthroplasty and ROSA® Hip System for total hip replacement.

Key Points: 
  • WARSAW, Ind., Feb. 22, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the ROSA® Shoulder System for robotic-assisted shoulder replacement surgery.
  • ROSA Shoulder is the world's first robotic surgery system for shoulder replacement, and the fourth application for the Company's comprehensive ROSA® Robotics portfolio, which includes the ROSA® Knee System for total knee arthroplasty and ROSA® Hip System for total hip replacement.
  • ROSA Shoulder strengthens Zimmer Biomet's innovative shoulder implant portfolio, which includes the Identity Shoulder System, and joins ZBEdge™ Dynamic Intelligence™ , which has the power to enhance the company's cutting-edge digital technologies, robotics and implant solutions.
  • "We are proud and excited to be the first company in the world to deliver a robotic surgical assistant for anatomic and reverse shoulder replacement surgery," said Ivan Tornos, President and Chief Executive Officer at Zimmer Biomet.

Elephas to Collaborate with Mayo Clinic to Advance Development of Oncology Imaging Diagnostics Platform

Retrieved on: 
Tuesday, February 20, 2024
Patient, Mayo Clinic, Observational study, Immunotherapy, Cancer

MADISON, Wis., Feb. 20, 2024 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas), a biotechnology company, today announced that it will collaborate on the development of an oncology imaging diagnostics platform to predict response to immunotherapy with Mayo Clinic Comprehensive Cancer Center. The Elephas platform utilizes live patient biopsies with intact native tumor architecture and treats them with potential immunotherapies to predict response to treatment. The basis of the platform is to visualize immune cell activity including T cell activation and cytotoxic mediated killing. 

Key Points: 
  • MADISON, Wis., Feb. 20, 2024 /PRNewswire/ -- Elephas Biosciences Corporation (Elephas), a biotechnology company, today announced that it will collaborate on the development of an oncology imaging diagnostics platform to predict response to immunotherapy with Mayo Clinic Comprehensive Cancer Center.
  • The Elephas platform utilizes live patient biopsies with intact native tumor architecture and treats them with potential immunotherapies to predict response to treatment.
  • This collaboration brings together the Elephas team and Mayo Clinic researchers and medical oncologists to advance the Elephas platform.
  • In addition, researchers will collaborate on translational research utilizing Elephas' proprietary instruments, which are essential components of the diagnostic platform.

New Chair and Executive Committee Members Appointed of Lymphoma Research Foundation Mantle Cell Lymphoma Consortium

Retrieved on: 
Thursday, February 15, 2024
University, SAB, Haematopoietic system, Ohio State University, LRF, Clinical professor, Health, Associate, Diagnosis, McGill University, City, Mantle cell lymphoma, MCL, Tampa General Hospital, Weill Cornell Medicine, MCLC, Internal medicine, Clinical trial, Research, Faculty, Division, MD, NHL, Cancer Institute, Cell, Executive Committee, Society, Mayo Clinic, Non-Hodgkin lymphoma, Disease, Rush University, Pharmaceutical industry

NEW YORK, Feb. 15, 2024 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation (LRF) – the nation's largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services – is pleased to announce Tycel Phillips, MD of City of Hope and Kami Maddocks, MD of Ohio State University to the Executive Committee members and Peter Martin, MD of Weill Cornell Medicine as Chair of its Mantle Cell Lymphoma Consortium (MCLC) Executive Committee.

Key Points: 
  • "LRF's Mantle Cell Lymphoma Consortium provides a unique forum for the world's leading MCL researchers to share scientific and clinical findings, exchange ideas, and plan new collaborations," said Meghan Gutierrez, CEO of the Lymphoma Research Foundation
    The Mantle Cell Lymphoma Consortium Executive Committee helps to guide the MCLC by identifying gaps in research and patient care for this historically understudied patient population.
  • Since its inception the Mantle Cell Lymphoma Consortium brings together leading international experts to discuss the latest research findings, foster collaboration within the mantel cell lymphoma (MCL) research community, create new directions for research, and ultimately improve diagnosis and treatment for this disease.
  • "The Lymphoma Research Foundation's Mantle Cell Lymphoma Consortium provides a unique forum for the world's leading MCL researchers to share scientific and clinical findings, exchange ideas, and plan new collaborations," said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation.
  • "I'm honored to lead this vital consortium dedicated to improving outcomes for all those impacted by mantle cell lymphoma," said Dr. Martin.